A French single-center experience on allogeneic stem cell transplant cryopreservation during severe acute respiratory syndrome coronavirus 2 pandemic

[1]  Xiao-hui Zhang,et al.  Hematopoietic Stem Cell Transplantation Activity in China 2020–2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry Group , 2022, Transplantation and Cellular Therapy.

[2]  Y. Kanda,et al.  Cryopreservation of Unrelated Hematopoietic Stem Cells from a Blood and Marrow Donor Bank During the COVID-19 Pandemic: A Nationwide Survey by the Japan Marrow Donor Program , 2021, Transplantation and Cellular Therapy.

[3]  D. Benhamou,et al.  ICU bed capacity during COVID-19 pandemic in France: From ephemeral beds to continuous and permanent adaptation , 2021, Anaesthesia Critical Care & Pain Medicine.

[4]  S. Devine,et al.  Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products , 2020, Transplantation and Cellular Therapy.

[5]  P. Chiusolo,et al.  Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal , 2020, Cytotherapy.

[6]  I. Schmale.  European Society for Blood and Marrow Transplantation , 2020, Onkologische Welt.

[7]  D. Curtis,et al.  Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic , 2020, Blood advances.

[8]  S. Montoto,et al.  The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy , 2020, Bone Marrow Transplantation.

[9]  C. Quinto,et al.  Coronavirus Disease 2019 , 2020, Clinics in Geriatric Medicine.

[10]  J. Szer,et al.  The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage , 2020, Bone Marrow Transplantation.

[11]  Le Chang,et al.  Coronavirus Disease 2019: Coronaviruses and Blood Safety , 2020, Transfusion Medicine Reviews.

[12]  A. Chanan-Khan,et al.  Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies. , 2020, JCO oncology practice.

[13]  J. Oldenburg,et al.  Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. , 2016, Cytotherapy.

[14]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[15]  J. Ferrara,et al.  Advances in predicting acute GVHD , 2013, British journal of haematology.

[16]  D. Paniagua,et al.  Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  F. Massin,et al.  Validation of a single-platform method for hematopoietic CD34+ stem cells enumeration according to accreditation procedure. , 2015, Bio-medical materials and engineering.

[18]  J. Stoltz,et al.  Thawed autologous peripheral blood stem cells require modified quantification methods for hematopoietic progenitor cell evaluation. , 2012, Bio-medical materials and engineering.

[19]  F. Appelbaum,et al.  Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. , 1978, Blood.